Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Barraco

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Current Cancer Drug Targets|March 10, 2018
Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled AnalysisFrancesco Passiglia, Sergio Rizzo, Christian Rolfo, et al.
Cancers|August 29, 2020
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond <i>BRCA1/2</i>Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo, et al.
Therapeutic Advances in Medical Oncology|October 14, 2021
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analysesValerio Gristina, Antonio Galvano, Luisa Castellana, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 5, 2016
Dietary restriction: could it be considered as speed bump on tumor progression road?Antonina Cangemi, Daniele Fanale, Gaetana Rinaldi, et al.
Cancers|May 9, 2020
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in <i>BRCA1/2</i> GenesLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Advances in Therapy|August 22, 2019
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Therapeutic Advances in Medical Oncology|September 20, 2019
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysisAntonio Galvano, Simona Taverna, Giuseppe Badalamenti, et al.
Expert Review of Molecular Diagnostics|August 8, 2023
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?Valerio Gristina, Pasquale Pisapia, Nadia Barraco, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 22, 2016
A headlight on liquid biopsies: a challenging tool for breast cancer managementDaniela Massihnia, Alessandro Perez, Viviana Bazan, et al.
Therapeutic Advances in Medical Oncology|August 28, 2020
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI scoreAntonio Galvano, Marta Peri, Aurelia Ada Guarini, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Current Cancer Drug Targets|March 10, 2018
Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled AnalysisFrancesco Passiglia, Sergio Rizzo, Christian Rolfo, et al.
Cancers|August 29, 2020
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond <i>BRCA1/2</i>Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo, et al.
Therapeutic Advances in Medical Oncology|October 14, 2021
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analysesValerio Gristina, Antonio Galvano, Luisa Castellana, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 5, 2016
Dietary restriction: could it be considered as speed bump on tumor progression road?Antonina Cangemi, Daniele Fanale, Gaetana Rinaldi, et al.
Cancers|May 9, 2020
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in <i>BRCA1/2</i> GenesLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Advances in Therapy|August 22, 2019
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Therapeutic Advances in Medical Oncology|September 20, 2019
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysisAntonio Galvano, Simona Taverna, Giuseppe Badalamenti, et al.
Expert Review of Molecular Diagnostics|August 8, 2023
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?Valerio Gristina, Pasquale Pisapia, Nadia Barraco, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 22, 2016
A headlight on liquid biopsies: a challenging tool for breast cancer managementDaniela Massihnia, Alessandro Perez, Viviana Bazan, et al.
Therapeutic Advances in Medical Oncology|August 28, 2020
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI scoreAntonio Galvano, Marta Peri, Aurelia Ada Guarini, et al.
Pageof 4